UPDATE 1-Warner Chilcott’s new oral contraceptive gets FDA nod

* Says new contraceptive offers lowest dose of estrogen

* Sees launching drug in early 2011

* Shares up 3 pct

Oct 22 (BestGrowthStock) – Specialty pharmaceutical company Warner
Chilcott Plc (WCRX.O: ) said the U.S. health regulator approved
its new low-dose oral contraceptive, Lo Loestrin Fe, sending
its shares up 3 percent in pre-market trade.

The company expects to launch the drug in early 2011.

Lo Loestrin Fe is an oral contraceptive that has the lowest
dosage of estrogen at 10 micrograms (mcg), compared with any
oral contraceptive currently available in the U.S. market,
Warner Chilcott said in a statement.

The company, which is focused on women’s healthcare, has a
few other oral contraceptives on the market, including Loestrin
24 Fe that contained the lowest dose of 20 mcg of estrogen till
now.

Estrogen is the main female sex hormone and plays an
important role in the menstrual cycle.

The company’s shares, which have gained 7 percent since its
postmenopausal osteoporosis treatment got regulatory approval
earlier this month, were up 3 percent at $24.61 in pre-market
trade. They closed at $23.91 Thursday on Nasdaq.
(Reporting by Esha Dey in Bangalore; Editing by Aradhana
Aravindan)

UPDATE 1-Warner Chilcott’s new oral contraceptive gets FDA nod